Navigation Links
Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
Date:10/4/2007

stant bacteria, not vaccine use."

Since the introduction of PREVNAR in the United States in 2000, the rate of antibiotic-resistant IPD decreased through 2004 by 98 percent (95% CI: 97.6-98.4) for vaccine serotypes and 81 percent (95% CI: 80-82) for all serotypes in children younger than two years of age.

Wyeth has a 13-valent pneumococcal conjugate vaccine in late-stage development that includes serotype 19A, as well as serotypes 1, 3, 5, 6A and 7F, in addition to the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) included in PREVNAR. The investigational 13-valent vaccine currently is in global Phase 3 clinical trials and may offer broader coverage than the 7- valent vaccine.

In view of the demonstrated vaccine efficacy and high disease burden in young children, the World Health Organization (WHO) recently recommended priority inclusion of the pneumococcal conjugate vaccine in national immunization programs worldwide. The Advisory Committee on Immunization Practices for the Centers for Disease Control and Prevention recommends pneumococcal conjugate vaccine for all infants as do many other countries. PREVNAR, the only licensed pneumococcal conjugate vaccine, now is available in more than 80 countries worldwide and is part of the routine national childhood immunization schedule in 17 of these countries.

Pneumococcal Disease

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media and sinusitis. WHO estimates that pneumococcal disease results in up to one million deaths each year in young children worldwide. Further, according to WHO, pneumococcal disease is the number one vaccine-preventable cause of death in children less
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. Northfield Labs Receives FDA Comments
7. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
8. Trendsetters: Little girls fast track into ladies even before they know it
9. Periodontal disease can be predicted by trends in obesity!
10. Romantic and discreet trends in lingerie
11. Stringent budget for 2006/2007 portends unhealthy trends for HIV/AIDS patients.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 Coral Gables is ... service , Lice Troopers, with its new clinic location set ... Florida, takes the hassle out of dealing with this common ... one of their two salon clinic locations in South Florida, ... location. , The decision to expand developed naturally out of ...
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... 03, 2007 - Gastroesophageal reflux disease (GERD), often known ... been associated with cancers, asthma, recurrent aspiration and pulmonary ... of Gastroenterology examines whether GERD sufferers may have shorter ... on over 50,000 person-years of data, the study provides ...
... CAMBRIDGE, Mass., Jan. 3, 2008 -- Psychologists at Harvard ... perception that, they argue, can resolve the century-old debate ... not only illustrates a new method for studying such ... against the existence of extrasensory perception, or ESP. , ...
... 23 million Americans age 12 or older need treatment for ... than 10 percent actually receive it. Worse, among those ... treatments that are known to work. , We have treatments ... Paul Roman, University of Georgia Distinguished Research Professor of Sociology ...
... VICTORIA, Jan. 3 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... completion of the,plan of arrangement with Galenica Group ... Canadian subsidiary, acquired all,outstanding shares of Aspreva for ... completion of the plan of arrangement, Aspreva will ...
... Jan. 3 DaVita Inc. (NYSE:,DVA) announced today that ... January 7-11, 2008 at the Westin St. Francis Hotel ... will be presenting on,January 8, at 9:00 a.m. Pacific ... presentation will also be broadcast live and by replay. ...
... The Jeffrey Modell Foundation drives initiative for SCID screening, ... became the first,state in the nation to screen all ... "Bubble Boy Disease," SCID is a,genetic disorder that is ... referred for potentially life-saving treatment., The Wisconsin Department ...
Cached Medicine News:Health News:Researchers use neuroimaging to study ESP 2Health News:Researchers use neuroimaging to study ESP 3Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 2Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 3Health News:Aspreva's plan of arrangement with Galenica completed 2Health News:Aspreva's plan of arrangement with Galenica completed 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 2Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 4Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 5
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Disease Market to 2017 - Patent ... as Aricept, Namenda, Avonex, Rebif and ...
... Leading events organiser UBM Live , a division ... a new event, CPhI South East Asia to cater to ... 10 to 12 May at the Jakarta International Expo in ... pharmaceutical events is being introduced to offer a meeting place ...
Cached Medicine Technology:Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15CPhI Global Portfolio Expands into South East Asia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: